Antiplatelet activity of synthetic pyrrolo-benzylisoquinolines

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 5, 2003, Pages 821-823

  Kuo, Reen Yen ^a   Wu, Chin Chung ^a   Chang, Fang Rong ^a   Yeh, Jwu Lai ^a   Chen, Ing Jun ^a   Wu, Yang Chang ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR; ARACHIDONIC ACID; BENZYLISOQUINOLINE DERIVATIVE; COLLAGEN;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SPECIFICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; THROMBOCYTE AGGREGATION;

EID: 0037430645     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00003-9     Document Type: Article

References (23)

1. Bentley K.W. Nat. Prod. Rep. 15:1998;341.
2. Bentley K.W. Nat. Prod. Rep. 16:1999;367.
3. Bentley K.W. Nat. Prod. Rep. 17:2000;247.
4. Bentley K.W. Nat. Prod. Rep. 18:2001;148.
5. Bentley K.W. Nat. Prod. Rep. 19:2002;332.
6. Barton D.H.R., Kirby G.W., Steglich W.G., Thomas M., Battersby A.R., Dobson T.A., Ramuz H. J. Chem. Soc. 1965;2423.
7. Weber S., Brandom B.W., Powers D.M., Sarner J.B., Woelfel S.K., Cook D.R., Foster V.J., McNulty B.F., Weakly J.N. Anesth. Analg. 67:1988;495.
8. Hofer C., Zalunardo M.P., Zollinger A. Anaesthesia. 56:2001;1082.
9. Diefenbach C., Mellinghoff H. Anaesthesist. 46:1997;385.
10. Iwasa K., Moriyasu M., Tachibana Y., Kim H.S., Wataya Y., Wiegrebe W., Bastow K.F., Cosentino L.M., Kozuka M., Lee K.H. Bioorg. Med. Chem. 11:2001;2871.
11. Kupchan S.M., Altland H.W. J. Med. Chem. 16:1973;913.
12. Penn R.B., Parent J.L., Pronin A.N., Panettieri R.A. Jr., Benovic J.L. J. Pharmacol. Exp. Ther. 288:1999;428.
13. Lin C.H., Yang C.M., Chen C.M., Ko F.N., Teng C.M. Pharmacology. 53:1996;19.
14. Puia G., Santi M.R., Vicini S., Pritchett D.B., Seeburg P.H., Costa E. Proc. Natl. Acad. Sci. U.S.A. 86:1989;7275.
15. Basile A.S., Bolger G.T., Lueddens H.W., Skolnick P. J. Pharmacol. Exp. Ther. 248:1989;463.
16. Castedo L., Saã C., Saã J.M., Suau R. J. Org. Chem. 47:1982;513.
17. Cobas A., Guitiãn E., Castedo L. J. Org. Chem. 57:1992;6765.
18. abstract
19. Antiplatelet aggregation assays: see: Chen K.S., Ko F.N., Teng C.M., Wu Y.C. Planta Med. 62:1996;133.
20. 2) binding affinity assays: see: Huang Y.C., Yeh J.L., Wu B.N., Lo Y.C., Liang J.C., Lin Y.T., Sheu S.H., Chen I.J. Drug Develop. Res. 47:1999;77 (b) Lin Y.T., Wu B.N., Horng C.H., Huang Y.C., Horng S.J., Lo Y.C., Cheng C.J., Chen I.J. Jpn. J. Pharmacol. 80:1999;127.
21. 2) binding affinity assays: see: Huang Y.C., Yeh J.L., Wu B.N., Lo Y.C., Liang J.C., Lin Y.T., Sheu S.H., Chen I.J. Drug Develop. Res. 47:1999;77 (b) Lin Y.T., Wu B.N., Horng C.H., Huang Y.C., Horng S.J., Lo Y.C., Cheng C.J., Chen I.J. Jpn. J. Pharmacol. 80:1999;127.
22. (a) Cytotoxicity assay: Cancer cells were seeded in 96-well microtiter plates at a density of 6000/well in 100 μL culture medium. After an overnight adaptation period, 10 μM/mL (final concentration) of test compounds in serium-free medium were added to individual wells. Cells were treated with test compounds for three days. Cell viability was determined by the 5-(3-carbonylmethoxyphenyl)-2-(4,5-dimethylthazolyl)-3-(4-silfophenyl) tetrazolium salt (MTS) reduction. Actinomycin D 5μM (final concentration) and DMSO 0.1% (final concentration) were used as positive and vehicle controls. Results were expressed as percent of DMSO control. For details of the assay protocols, see: Gieni R.S., Li Y., HayGlass K.T. J. Immunol. Meth. 187:1995;85 (b) Malich G., Markovic B., Winder C. Toxicology. 124:1997;179.
23. (a) Cytotoxicity assay: Cancer cells were seeded in 96-well microtiter plates at a density of 6000/well in 100 μL culture medium. After an overnight adaptation period, 10 μM/mL (final concentration) of test compounds in serium-free medium were added to individual wells. Cells were treated with test compounds for three days. Cell viability was determined by the 5-(3-carbonylmethoxyphenyl)-2-(4,5-dimethylthazolyl)-3-(4-silfophenyl) tetrazolium salt (MTS) reduction. Actinomycin D 5μM (final concentration) and DMSO 0.1% (final concentration) were used as positive and vehicle controls. Results were expressed as percent of DMSO control. For details of the assay protocols, see: Gieni R.S., Li Y., HayGlass K.T. J. Immunol. Meth. 187:1995;85 (b) Malich G., Markovic B., Winder C. Toxicology. 124:1997;179.